Jump to ContentJump to Main Navigation
Human Genome Epidemiology, 2nd EditionBuilding the evidence for using genetic information to improve health and prevent disease$
Users without a subscription are not able to see the full content.

Muin Khoury, Sara Bedrosian, Marta Gwinn, Julian Higgins, John Ioannidis, and Julian Little

Print publication date: 2009

Print ISBN-13: 9780195398441

Published to Oxford Scholarship Online: May 2010

DOI: 10.1093/acprof:oso/9780195398441.001.0001

Show Summary Details
Page of

PRINTED FROM OXFORD SCHOLARSHIP ONLINE (www.oxfordscholarship.com). (c) Copyright Oxford University Press, 2019. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a monograph in OSO for personal use (for details see www.oxfordscholarship.com/page/privacy-policy).date: 17 July 2019

The role of epidemiology in assessing the potential clinical impact of pharmacogenomics

The role of epidemiology in assessing the potential clinical impact of pharmacogenomics

Chapter:
(p.533) 27 The role of epidemiology in assessing the potential clinical impact of pharmacogenomics
Source:
Human Genome Epidemiology, 2nd Edition
Author(s):

David L. Veenstra

Publisher:
Oxford University Press
DOI:10.1093/acprof:oso/9780195398441.003.0027

A promising area of genomics is the use of information about genetic variation to guide drug therapy, a field known as pharmacogenomics. Pharmacogenomic applications can be broadly categorized into (a) those related to variation in drug metabolism and disposition genes, which affect the levels of active drug or metabolites in the body and thus both effectiveness and side effects; and (b) those related to variation in genes for drug targets, which primarily influence the effectiveness of a drug. These categories can be applied to both inherited and acquired variation. This chapter discusses the role of epidemiology in assessing pharmacogenomic associations, as well as approaches utilizing epidemiologic data to quantify the potential benefits and harms of pharmacogenomic tests in clinical use.

Keywords:   pharmacogenomics, epidemiological data, genetic information, genetic variation, drug therapy

Oxford Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs , and if you can't find the answer there, please contact us .